Prevention and treatment of postmenopausal osteoporosis
Top Cited Papers
- 1 July 2014
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 142, 155-170
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 yearsOsteoporosis International, 2012
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Hip fracture in postmenopausal women after cessation of hormone therapyMenopause, 2011
- Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women's Health Across the Nation (SWAN)Journal of Bone and Mineral Research, 2011
- Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled studyOsteoporosis International, 2011
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Vitamin D DeficiencyNew England Journal of Medicine, 2007
- Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trialClimacteric, 2005
- Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without OsteoporosisJournal of Bone and Mineral Research, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002